{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83c\udf0d Stroke Frontiers: Six Global Trials Changing Practice","description":"\ud83e\udde0 Six landmark stroke investigations published in NEJM, JAMA, and Lancet are redefining modern reperfusion science. &amp;nbsp; \ud83d\udd39 ORIENTAL-MeVO: Thrombectomy improved outcomes in selected medium-vessel occlusion strokes. \ud83d\udd39 TNK-PLUS: Bridging tenecteplase before EVT in the late window showed no added benefit. \ud83d\udd39 CHOICE-2: Intra-arterial alteplase after successful thrombectomy improved excellent recovery but raised mortality concerns. \ud83d\udd39 INSTANT: Early tirofiban after inadequate tenecteplase response improved 90-day outcomes. \ud83d\udd39 TAPIS: Early ticagrelor + aspirin after thrombolysis improved functional recovery without excess major bleeding. \ud83d\udd39 ATLAS: EVT benefited large-core stroke patients up to 24 hours after onset. &amp;nbsp; Together, these studies shift the conversation from simply reopening arteries toward optimizing tissue-level reperfusion, patient selection, and microvascular recovery. \ud83d\ude91\u26a1 &amp;nbsp; #Stroke #Neurology #Thrombectomy #JAMA #NEJM #Lancet #Neurointervention #Tenecteplase #Tirofiban #Cardiology ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41301735\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/201969010"}